/stocks — the workspaceLOADING
IONIS PHARMACEUTICALS INC (IONS) is a pharmaceutical preparations company. Piotroski F-Score 4/8. 28 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-07-29 from IONS's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
A plain-English read on IONS plus an auto-SWOT — built from IONS's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate IONS using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Kordasiewicz Holly B.EVP, Chief Development Officer | SELL | $31K | view → |
| Diaz Allene M.Director | SELL | $864K | view → |
| BENNETT C FRANKEVP, Chief Scientific Officer | SELL | $1.7M | view → |
| KLEIN JOSEPH IIIDirector | SELL | $910K | view → |
| Schneider EugeneEVP, Chf Clinical Develop Ofcr | SELL | $2.1M | view → |
| O'NEIL PATRICK R.EVP CLO & General Counsel | SELL | $246K | view → |
| Baroldi JosephEVP, Chief Business Officer | SELL | $452K | view → |
| Swayze EricEVP Research | SELL | $839K | view → |
| Tweedy Browne | $170.9M | 13.6% of portfolio |
Projected from IONS's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment IONS files its announcement.
IONS has rallied after 5 of its last 8 earnings reports.
Earnings reactions have been moderate.
IONS has traded higher after most recent earnings releases.
The average is inflated by its most volatile prints (+6.4% and -5.7%).
A more typical earnings reaction has been approximately ±3.0%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-04-29 | +4.2% |
| 2026-02-25 | -5.7% |
| 2026-01-12 | -1.0% |
| 2025-10-29 | +0.8% |
| 2025-07-30 | +3.6% |
| 2025-04-30 | +6.4% |
| 2025-02-19 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +2.3% |
| 2024-11-06 | -0.9% |